Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Dec 21;21(1):96.
doi: 10.3390/ijms21010096.

Urinary Peptidomic Biomarkers in Kidney Diseases

Vittorio Sirolli  1 , Luisa Pieroni  2 , Lorenzo Di Liberato  1 , Andrea Urbani  3   4 , Mario Bonomini  1
Affiliations
Review

Urinary Peptidomic Biomarkers in Kidney Diseases

Vittorio Sirolli et al. Int J Mol Sci. .

Abstract

In order to effectively develop personalized medicine for kidney diseases we urgently need to develop highly accurate biomarkers for use in the clinic, since current biomarkers of kidney damage (changes in serum creatinine and/or urine albumin excretion) apply to a later stage of disease, lack accuracy, and are not connected with molecular pathophysiology. Analysis of urine peptide content (urinary peptidomics) has emerged as one of the most attractive areas in disease biomarker discovery. Urinary peptidome analysis allows the detection of short and long-term physiological or pathological changes occurring within the kidney. Urinary peptidomics has been applied extensively for several years now in renal patients, and may greatly improve kidney disease management by supporting earlier and more accurate detection, prognostic assessment, and prediction of response to treatment. It also promises better understanding of kidney disease pathophysiology, and has been proposed as a "liquid biopsy" to discriminate various types of renal disorders. Furthermore, proteins being the major drug targets, peptidome analysis may allow one to evaluate the effects of therapies at the protein signaling pathway level. We here review the most recent findings on urinary peptidomics in the setting of the most common kidney diseases.

Keywords: CKD; biomarker; clinical proteomics; kidney; mass spectrometry; peptidomics; urine.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Webster A.C., Nagler E.V., Morton R.L., Masson P. Chronic kidney disease. Lancet. 2017;389:1238–1252. doi: 10.1016/S0140-6736(16)32064-5. - DOI - PubMed
    1. Chen L., Su W., Chen H., Chen D.-Q., Wang M., Guo Y., Zhao Y.-Y. Proteomics for biomarker identification and clinical application in kidney disease. Adv. Clin. Chem. 2018;85:91–113. doi: 10.1016/bs.acc.2018.02.005. - DOI - PubMed
    1. Schievink B., Kropelin T., Mulder S., Parving H.H., Remuzzi G., Dwyer J., Vemer P., de Zeeuw D., Lambers Heerspink H.J. Early renin angiotensin system intervention is more beneficial than late intervention in delaying end-stage renal disease in patients with type 2 diabetes. Diabetes Obes. Metab. 2016;18:64–71. doi: 10.1111/dom.12583. - DOI - PubMed
    1. Thomas S., Hao L., Ricke W.A., Li L. Biomarker discovery in mass spectrometry-based urinary proteomics. Proteom. Clin. Appl. 2016;10:358–370. doi: 10.1002/prca.201500102. - DOI - PMC - PubMed
    1. Klein J., Bascands J.L., Mischak H., Schanstra J.P. The role of urinary peptidomics in kidney disease research. Kidney Int. 2016;89:539–545. doi: 10.1016/j.kint.2015.10.010. - DOI - PubMed